



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 29077

**Title:** Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment

**Reviewer's code:** 00029041

**Reviewer's country:** Japan

**Science editor:** Jin-Xin Kong

**Date sent for review:** 2016-07-29 16:55

**Date reviewed:** 2016-09-25 08:24

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

Although this review is well written, the discussion of the direct cost-effectiveness in the biologic era is lacking. Below papers would be helpful. Danese S, et al. Biologic agents for IBD: practical insights. *Nat Rev Gastroenterol Hepatol.* 2015 Sep;12(9):537-45. van der Valk ME, et al. Healthcare costs of inflammatory boweldisease have shifted from hospitalisation and surgery towards anti-TNF $\alpha$  therapy: results from the COIN study. *Gut.* 2014 Jan;63(1):72-9. Bernstein CN, et al. Direct medical cost of managing IBD patients: a Canadian population-based study. *Inflamm Bowel Dis.* 2012 Aug;18(8):1498-508.



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 29077

Title: Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment

Reviewer's code: 00033010

Reviewer's country: Italy

Science editor: Jin-Xin Kong

Date sent for review: 2016-07-29 16:55

Date reviewed: 2016-10-06 22:47

Table with 4 columns: CLASSIFICATION, LANGUAGE EVALUATION, SCIENTIFIC MISCONDUCT, CONCLUSION. It contains checkboxes for various evaluation criteria like 'Grade A: Excellent', 'Priority publishing', 'Google Search', etc.

COMMENTS TO AUTHORS

In the present paper, Actis and Pellicano analyzed the relationship between pharmacological therapy, remission maintenance and economic burden in inflammatory bowel disease (IBD). The Abstract is not informative and does not resume the content of the article, therefore it should be re-written. A linguistic revision is necessary. Authors report in page 5 only the use of ornidazole. However, ciprofloxacin and metronidazole are the most used molecules, therefore this paragraph should be more focused on the topic, and a more in-depth analysis about antibiotics is required. Authors should underline that currently intravenous cyclosporine is recommended only for a short duration time to prevent emergency surgery in ulcerative colitis. Cyclosporine is no longer recommended in oral formulation nor for Crohn's disease. In the conclusion paragraph, some sentences should be supported by adequate references. Apart from the above mentioned criticisms, this is a good quality article.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 29077

**Title:** Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment

**Reviewer's code:** 00008134

**Reviewer's country:** Netherlands

**Science editor:** Jin-Xin Kong

**Date sent for review:** 2016-07-29 16:55

**Date reviewed:** 2016-08-24 15:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

This topic highlight by Actis et al. is generally important and well-written. The language meets the conditions for publication, however, minor language polishment has to be performed. Whilst this review provides an informative overview of the costs associated with hospital admissions, this reviewer would like to see a concise statement of costs associated with different drugs for treating IBD. Whereas treatment with anti-TNF agents seems obligatory in some patients, especially with fistulizing disease, this reviewer believes that optimized treatment with conventional agents (i.e. Mesalazines or thiopurines), or rediscovered agents (Thioguanine) might be sufficient in a significant part of the patient. Perhaps adding one or two sections regarding this topic combined with costs of drugs might strenghten this, in general, very informative paper.